Lucid Diagnostics Announces Business Update Conference Call Scheduled for November 12, 2026

Lucid Diagnostics Third Quarter 2026 Update

Lucid Diagnostics Inc. (Nasdaq: LUCD), renowned for its pioneering cancer prevention medical diagnostic tools, has made headlines with the announcement of its upcoming business update conference call. Scheduled for November 12, 2026, at 8:30 AM ET, this call is set to be a significant event for stakeholders and industry enthusiasts alike.

Dr. Lishan Aklog, who serves as both the Chairman and CEO of Lucid, will lead the conference. He is expected to provide valuable insights into the company's operations, strategic growth plans, and the market landscape for their innovative diagnostic solutions. This includes an overview of the company's proprietary technologies aimed at addressing the medical needs in the area of gastroesophageal reflux disease (GERD).

During the call, Lucid's Chief Financial Officer, Dennis McGrath, will present the third quarter 2026 financial results. This analysis will be crucial in assessing the company’s performance and future potentials in the rapidly evolving medical diagnostics field.

For those interested in joining the call, it can be accessed via telephone for U.S. participants at 1-800-836-8184, and international listeners can call 1-646-357-8785. Participants will need to mention the conference call name "Lucid Diagnostics Business Update" to gain entry.

Additionally, the webcast of the conference will be made available through the investor relations section of Lucid's official website, www.luciddx.com. Following the live event, a replay will also be accessible for 30 days, ensuring that all interested parties can stay informed about the insights shared during the call.

Lucid Diagnostics, a subsidiary of PAVmed Inc. (Nasdaq: PAVM), focuses on providing accurate and noninvasive diagnostic solutions for patients suffering from GERD, a condition linked to increased risk of esophageal cancer. Their flagship product, the EsoGuard® Esophageal DNA Test, represents a groundbreaking advancement in early cancer detection. By utilizing samples collected through a brief and easy procedure with the EsoCheck® device, the company aims to significantly reduce the risk of cancer deaths through decisive early intervention.

As awareness of the critical nature of early cancer detection continues to grow, Lucid’s commitment to advancing diagnostic processes is positioned to make a substantial impact. This upcoming conference call serves as an essential avenue for investors and healthcare professionals to gain insights into the future direction and advancements being made by Lucid Diagnostics.

For more information about Lucid’s offerings and its parent company, the public is encouraged to visit Lucid Diagnostics and PAVmed.

Stay tuned as Lucid Diagnostics continues to unfold its story at the intersection of medicine, technology, and patient care, highlighting the importance of cancer prevention and early detection.